Integrated Continuous Glucose Monitoring System, Factory Calibrated(QBJ)
一体型持続グルコースモニタリングシステム(工場校正式) この日本語名は AI が生成した参考訳です。正式名称は英語の原名です。
23 件
直近 2026.07.01
18 件
0 件
2,268,268 件
分類情報
| Product Code | QBJ |
|---|---|
| デバイス名 | Integrated Continuous Glucose Monitoring System, Factory Calibrated 一体型持続グルコースモニタリングシステム(工場校正式) この日本語名は AI が生成した参考訳です。正式名称は英語の原名です。 |
| デバイスクラス | クラス II |
| 21 CFR 規制番号 | 862.1355 |
| 審査区分 | 510(k)(市販前届出) |
| 医療専門分野 | 臨床化学 |
| 定義 | An integrated continuous glucose monitoring system (iCGM) is intended to automatically measure glucose in bodily fluids continuously or frequently for a specified period of time. iCGM systems are designed to reliably and securely transmit glucose measurement data to digitally connected devices, including automated insulin dosing systems, and are intended to be used alone or in conjunction with these digitally connected medical devices for the purpose of managing a disease or condition related to glycemic control. 一体型持続グルコースモニタリングシステム(iCGM)は、体液中のグルコースを一定期間にわたり連続的又は頻回に自動的に測定することを目的とする。iCGMシステムは、自動インスリン投与システムを含むデジタル接続機器へグルコース測定データを確実かつ安全に伝送するように設計されており、血糖管理に関連する疾患又は状態を管理する目的で、単独で、又はこれらのデジタル接続医療機器と併用して使用されることを意図している。 この日本語訳は AI が生成した参考訳です。正確な内容は英語の原文をご確認ください。 |
| フラグ | 該当なし |
| AI分析 | 本製品は米国においてクラスIIに分類され、市販前届出(510(k))による審査を経て市場に出されます。クラスIIはクラスIIIに求められる市販前承認(PMA)ほど厳格な審査を必要としないものの、有効性及び安全性を確保するために一定の性能基準を満たすことが求められる中程度のリスク区分です。本製品は臨床化学分野に属する機器として分類されており、血糖管理のためにデジタル接続機器と連携して機能する点が規制上の特徴となっています。 米国市場での動向 本製品区分では510(k)届出が累計約20件あり、直近5年で約10件、参入企業は2社となっています。不具合報告(MDR)は累計約215万件と多数にのぼり、その大半が不具合(Malfunction)に関するもので、死亡報告は219件、傷害報告は約39,000件確認されています。回収は累計約20件で、うちクラスI(最重篤)が10件、クラスIIが13件含まれており、クラスIIIの回収は確認されていません。最新の回収は2026年5月に開始されており、主な根本原因としてソフトウェア設計(Software design)、不適合材料・部品(Nonconforming Material/Component)、環境管理(Environmental control)が挙げられています。 この分析は公開データ(openFDA・JMDN 対応情報)をもとに AI が生成した参考情報です。市場データは2026年8月時点の集計に基づきます。 |
関連 product code
同じ 21 CFR 862.1355 に分類される product code(6 件)
| No. | product code | 機器名 | クラス | 専門分野 | 510(k) | PMA | 不具合 | 回収 |
|---|---|---|---|---|---|---|---|---|
| 1 | QLG | Integrated Continuous Glucose Monitoring System, Factory Calibrated, Not For Use With Automated Insulin Delivery Systems インテグレーテッド持続血糖測定システム(工場出荷時校正済み、自動インスリン投与システム非対応) | II | 臨床化学 | 9 | — | 213,817 | 10 件 |
| 2 | QDK | Integrated Continuous Glucose Monitoring System For Non-Intensive Diabetes Management 統合型持続血糖測定システム(非強化糖尿病管理用) | II | 臨床化学 | 4 | — | 619 | — |
| 3 | SAF | Integrated Continuous Glucose Monitor For Non-Intensive Glucose Monitoring, Over-The-Counter 非強化インスリン療法用一般用一体型持続血糖測定システム | II | 臨床化学 | 4 | — | 2,699 | — |
| 4 | SBH | Integrated Continuous Glucose Monitor For Non-Intensive Glucose Management, Over-The-Counter 非強化インスリン療法用一体型持続グルコースモニタ(一般用) | II | 臨床化学 | 3 | — | 2 | — |
| 5 | QDL | Integrated Continuous Glucose Monitoring System For Professional Retrospective Use 専門家用retrospective使用継続的血糖モニタリングシステム | II | 臨床化学 | 1 | — | — | — |
| 6 | QII | Integrated Continuous Glucose Monitoring System For Professional Directed Retrospective Or Real-Time Use 専門家指導下遡及的又はリアルタイム使用のための統合型持続グルコースモニタリングシステム | II | 臨床化学 | 1 | — | 237 | — |
機器名の日本語訳は AI により自動生成したものです。正確には英語原文をご確認ください。
類似の国内医療機器(自動推定)
FDA デバイス分類と JMDN 英語名の名称・定義文の類似度から機械的に推定した候補です。日米の当局が定めた公的な対応関係ではなく、参考情報としてご覧ください。
| No. | 類別 | 一般的名称 | 品目数 | 企業数 | 年間総出荷額 | 成長率 | 平均価格 | 国産比率 |
|---|---|---|---|---|---|---|---|---|
| 1 | 体液検査用器具 | グルコースモニタシステムクラスⅢ | 12 | 7 | 436.7 億円/年 | +16.1% | 5,804 円/個 | 0.0% |
| 2 | 尿検査又は糞便検査用器具 | 自己検査用尿糖計クラスⅡ | 1 | 1 | — | — | — | — |
| 3 | 血液検査用器具 | 自己検査用グルコース測定器クラスⅢ | 44 | 13 | 15.69 億円/年 | -11.8% | 2,462 円/個 | 81.1% |
| 4 | 尿検査又は糞便検査用器具 | 電子尿糖計クラスⅡ | — | — | — | — | — | — |
| 5 | 血液検査用器具 | グルコース分析装置クラスⅠ | 45 | 13 | 5.75 億円/年 | -70.1% | 6.37 万円/個 | 90.7% |
FDA のデバイスクラスは 3 段階(クラス I〜III)、日本の医療機器は 4 段階(クラス I〜IV)で分類されており、 1 対 1 では対応しません。 リスク区分の考え方が異なるため、参考情報としてご利用ください。
米国での回収・承認・不具合報告
米国回収
全 23 件| 回収番号 | クラス | 回収開始日 | 企業 | 理由 | ステータス |
|---|---|---|---|---|---|
| Z-2574-2026 QBJ | クラス II | 2026.05.27 | Dexcom, Inc. | Certain lots of Dexcom G7 sensors originally designated as scrap and intended for destruction were stolen during the destruction process. The sensors were later sold to pharmacies and distributors by Pharmsource, LLC. Lot 1725204004 were designated for destruction because the G7 sensors were not properly sterilized and have an increased risk of skin infection if used. Lot 1725069002 were designated for destruction due to an increased risk of having no sensor readings available or experiencing sensor inaccuracy that includes the potential for missed detection of a hyperglycemic event or incorrect treatment decisions that can result in patient injury, including medical intervention to prevent permanent injury or impairment. Additionally, due to the unknown storage and handling and storage conditions these sensors may have undergone during the distribution, these sensors may present additional risk. | 対応中 |
| Z-2165-2026 QBJ | クラス II | 2026.04.14 | Dexcom, Inc. | A software defect in which a low-priority file I/O check blocks the higher-priority thread responsible for processing estimated glucose values (EGVs) and trend arrows. When the app is running in the background, EGV notifications may queue up and then "replay" sequentially when the user brings the app to the foreground, causing the Glucose Compass to flicker through previous EGVs. In more severe instances, the app may perceive signal loss and deploy signal loss mitigations. This delay in EGV and alert processing creates a risk that users may miss detection of a hypoglycemic or hyperglycemic event, or make treatment decisions based on outdated glucose information. | 対応中 |
| Z-2164-2026 QBJ | クラス II | 2026.04.14 | Dexcom, Inc. | A software defect in which a low-priority file I/O check blocks the higher-priority thread responsible for processing estimated glucose values (EGVs) and trend arrows. When the app is running in the background, EGV notifications may queue up and then "replay" sequentially when the user brings the app to the foreground, causing the Glucose Compass to flicker through previous EGVs. In more severe instances, the app may perceive signal loss and deploy signal loss mitigations. This delay in EGV and alert processing creates a risk that users may miss detection of a hypoglycemic or hyperglycemic event, or make treatment decisions based on outdated glucose information. | 対応中 |
| Z-2163-2026 QBJ | クラス II | 2026.04.14 | Dexcom, Inc. | A software defect in which a low-priority file I/O check blocks the higher-priority thread responsible for processing estimated glucose values (EGVs) and trend arrows. When the app is running in the background, EGV notifications may queue up and then "replay" sequentially when the user brings the app to the foreground, causing the Glucose Compass to flicker through previous EGVs. In more severe instances, the app may perceive signal loss and deploy signal loss mitigations. This delay in EGV and alert processing creates a risk that users may miss detection of a hypoglycemic or hyperglycemic event, or make treatment decisions based on outdated glucose information. | 対応中 |
| Z-0770-2026 QBJ | クラス II | 2025.11.03 | GET TESTED INTERNATIONAL AB | Distribution without premarket approval/clearance. | 対応中 |
| Z-0318-2026 QBJ | クラス I(最重篤) | 2025.08.28 | Dexcom, Inc. | A software defect in version v1.15.0 of the G6 Android app can cause the app to terminate unexpectedly, which may result in the user not receiving estimated glucose values, alarms, alerts or notifications. This could result in the missed detection of a hyperglycemic or hypoglycemic event, protentional resulting in severe hyperglycemia, diabetic ketoacidosis (DKA), or hyperosmolar hyperglycemic state (HHS). | 対応中 |
| Z-2450-2025 QBJ | クラス I(最重篤) | 2025.07.24 | Dexcom, Inc. | The affected devices are the Dexcom G7 Continuous Glucose Monitoring System (CGM System) using iOS, watchOS and Android App software (versions 2.8.0 or earlier) and Dexcom ONE+ CGM System using iOS and Android App software (versions 1.4.0 or earlier), henceforth referred to as the App. The affected App does not provide an expected "Sensor Failed" alert when the transmitter sends a "transmitterFailed" error message to the App when the CGM experiences a hardware or firmware failure. Instead, the App ends the CGM sensor session, stops reporting glucose values and displays the Start Sensor screen or No active sensor message without alerting the user, which can lead to missed detection of a hyperglycemic or hypoglycemic event and a delay in treatment. | 対応中 |
| Z-2449-2025 QBJ | クラス I(最重篤) | 2025.07.24 | Dexcom, Inc. | The affected devices are the Dexcom G7 Continuous Glucose Monitoring System (CGM System) using iOS, watchOS and Android App software (versions 2.8.0 or earlier) and Dexcom ONE+ CGM System using iOS and Android App software (versions 1.4.0 or earlier), henceforth referred to as the App. The affected App does not provide an expected "Sensor Failed" alert when the transmitter sends a "transmitterFailed" error message to the App when the CGM experiences a hardware or firmware failure. Instead, the App ends the CGM sensor session, stops reporting glucose values and displays the Start Sensor screen or No active sensor message without alerting the user, which can lead to missed detection of a hyperglycemic or hypoglycemic event and a delay in treatment. | 対応中 |
| Z-2448-2025 QBJ | クラス I(最重篤) | 2025.07.24 | Dexcom, Inc. | The affected devices are the Dexcom G7 Continuous Glucose Monitoring System (CGM System) using iOS, watchOS and Android App software (versions 2.8.0 or earlier) and Dexcom ONE+ CGM System using iOS and Android App software (versions 1.4.0 or earlier), henceforth referred to as the App. The affected App does not provide an expected "Sensor Failed" alert when the transmitter sends a "transmitterFailed" error message to the App when the CGM experiences a hardware or firmware failure. Instead, the App ends the CGM sensor session, stops reporting glucose values and displays the Start Sensor screen or No active sensor message without alerting the user, which can lead to missed detection of a hyperglycemic or hypoglycemic event and a delay in treatment. | 対応中 |
| Z-2447-2025 QBJ | クラス I(最重篤) | 2025.07.24 | Dexcom, Inc. | The affected devices are the Dexcom G7 Continuous Glucose Monitoring System (CGM System) using iOS, watchOS and Android App software (versions 2.8.0 or earlier) and Dexcom ONE+ CGM System using iOS and Android App software (versions 1.4.0 or earlier), henceforth referred to as the App. The affected App does not provide an expected "Sensor Failed" alert when the transmitter sends a "transmitterFailed" error message to the App when the CGM experiences a hardware or firmware failure. Instead, the App ends the CGM sensor session, stops reporting glucose values and displays the Start Sensor screen or No active sensor message without alerting the user, which can lead to missed detection of a hyperglycemic or hypoglycemic event and a delay in treatment. | 対応中 |
| Z-2446-2025 QBJ | クラス I(最重篤) | 2025.07.24 | Dexcom, Inc. | The affected devices are the Dexcom G7 Continuous Glucose Monitoring System (CGM System) using iOS, watchOS and Android App software (versions 2.8.0 or earlier) and Dexcom ONE+ CGM System using iOS and Android App software (versions 1.4.0 or earlier), henceforth referred to as the App. The affected App does not provide an expected "Sensor Failed" alert when the transmitter sends a "transmitterFailed" error message to the App when the CGM experiences a hardware or firmware failure. Instead, the App ends the CGM sensor session, stops reporting glucose values and displays the Start Sensor screen or No active sensor message without alerting the user, which can lead to missed detection of a hyperglycemic or hypoglycemic event and a delay in treatment. | 対応中 |
| Z-1946-2025 QBJ | クラス I(最重篤) | 2025.05.12 | Dexcom, Inc. | Defective foam or an assembly error may cause the receiver speaker to lose contact with the printed circuit board, leading to missed audible alerts for low or high blood glucose values. A missed audible alert for low or high blood glucose values could lead to untreated hypo or hyperglycemia which can cause seizures, vomiting, loss of consciousness, or death. | 対応中 |
| Z-1945-2025 QBJ | クラス I(最重篤) | 2025.05.12 | Dexcom, Inc. | Defective foam or an assembly error may cause the receiver speaker to lose contact with the printed circuit board, leading to missed audible alerts for low or high blood glucose values. A missed audible alert for low or high blood glucose values could lead to untreated hypo or hyperglycemia which can cause seizures, vomiting, loss of consciousness, or death. | 対応中 |
| Z-1944-2025 QBJ | クラス I(最重篤) | 2025.05.12 | Dexcom, Inc. | Defective foam or an assembly error may cause the receiver speaker to lose contact with the printed circuit board, leading to missed audible alerts for low or high blood glucose values. A missed audible alert for low or high blood glucose values could lead to untreated hypo or hyperglycemia which can cause seizures, vomiting, loss of consciousness, or death. | 対応中 |
| Z-1943-2025 QBJ | クラス I(最重篤) | 2025.05.12 | Dexcom, Inc. | Defective foam or an assembly error may cause the receiver speaker to lose contact with the printed circuit board, leading to missed audible alerts for low or high blood glucose values. A missed audible alert for low or high blood glucose values could lead to untreated hypo or hyperglycemia which can cause seizures, vomiting, loss of consciousness, or death. | 対応中 |
| Z-1906-2025 QBJ | クラス II | 2025.05.05 | Dexcom, Inc. | A bug in the 2.7.0 version of the G7 iOS App can cause the app to enter a state where it stops updating the estimated glucose value (EGV) and continues to show this stale EGV. If the user is unaware that the EGVs are not being updated and that glucose alerts will not trigger, there is potential for the missed detection of a hyperglycemic or hypoglycemic event or a treatment decision made based off incorrect data. There is no impact to transmitter communication with concurrently connected displays. A concurrently connected receiver, Apple Watch, and/or insulin pump will continue to receive EGVs directly from the transmitter when the app is in the problematic state. There is no impact to Automated Insulin Dosing (AID) therapy as the AID system continues to receive EGVs directly from the transmitter. | 対応中 |
| Z-1204-2025 QBJ | クラス II | 2025.01.27 | Dexcom, Inc. | Under very rare situations, the Dexcom G6 touchscreen receiver may not provide high or low glucose alarms/alerts as designed, which can result in two different conditions. First, if a receiver operating system .net error occurs when an alarm/alert should be triggered, the initial alarm/alert will not be delivered until a subsequent alarm/alert is triggered. At that time, the initial alarm/alert is delivered, but not the second one. Alarm/alerts will continue to be delayed and be one alarm/alert behind, causing delayed alarm/alerts until the receiver is reset. This condition could result in the missed detection of a hyperglycemic or hypoglycemic event. Second, a single EGV reading may be delayed for 5 minutes after the initial .net operating system error. If the user receives a single EGV reading delayed by 5 minutes, the delay is not expected to cause user harm. | 対応中 |
| Z-1203-2025 QBJ | クラス II | 2025.01.27 | Dexcom, Inc. | Under very rare situations, the Dexcom G6 touchscreen receiver may not provide high or low glucose alarms/alerts as designed, which can result in two different conditions. First, if a receiver operating system .net error occurs when an alarm/alert should be triggered, the initial alarm/alert will not be delivered until a subsequent alarm/alert is triggered. At that time, the initial alarm/alert is delivered, but not the second one. Alarm/alerts will continue to be delayed and be one alarm/alert behind, causing delayed alarm/alerts until the receiver is reset. This condition could result in the missed detection of a hyperglycemic or hypoglycemic event. Second, a single EGV reading may be delayed for 5 minutes after the initial .net operating system error. If the user receives a single EGV reading delayed by 5 minutes, the delay is not expected to cause user harm. | 対応中 |
| Z-1202-2025 QBJ | クラス II | 2025.01.27 | Dexcom, Inc. | Under very rare situations, the Dexcom G6 touchscreen receiver may not provide high or low glucose alarms/alerts as designed, which can result in two different conditions. First, if a receiver operating system .net error occurs when an alarm/alert should be triggered, the initial alarm/alert will not be delivered until a subsequent alarm/alert is triggered. At that time, the initial alarm/alert is delivered, but not the second one. Alarm/alerts will continue to be delayed and be one alarm/alert behind, causing delayed alarm/alerts until the receiver is reset. This condition could result in the missed detection of a hyperglycemic or hypoglycemic event. Second, a single EGV reading may be delayed for 5 minutes after the initial .net operating system error. If the user receives a single EGV reading delayed by 5 minutes, the delay is not expected to cause user harm. | 対応中 |
| Z-1934-2021 QBJ | クラス II | 2021.03.16 | Cardinal Health Inc. | Due to shipping delays the devices were exposed to temperature excursions of 31.9¿F, intermittently over a 2 hour and 15 minute period of time which may cause inaccurate results. | 対応中 |
510(k)(市販前届出)
全 18 件| No. | 番号 | 機器名 | 申請者 | 決定日 | 種別 | 概要 |
|---|---|---|---|---|---|---|
| 1 | K261402 | Dexcom G7 Continuous Glucose Monitoring System;Dexcom G7 15 Day Continuous Glucose Monitoring System | Dexcom, Inc. | 2026.06.08 | 通常(Traditional) | |
| 2 | K253737 | Dexcom G7 Continuous Glucose Monitoring (CGM) System; Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System | Dexcom, Inc. | 2026.02.03 | 通常(Traditional) | |
| 3 | K253710 | Dexcom G7 Continuous Glucose Monitoring (CGM) System, Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System | Dexcom, Inc. | 2025.12.17 | 特別(Special) | |
| 4 | K243214 | Dexcom G7 15 Day Continuous Glucose Monitoring System | Dexcom, Inc. | 2025.04.09 | 通常(Traditional) | |
| 5 | K240902 | Dexcom G7 Continuous Glucose Monitoring System | Dexcom, Inc. | 2024.04.23 | 特別(Special) | |
| 6 | K233537 | FreeStyle Libre 3 Continuous Glucose Monitoring System; FreeStyle Libre 2 Flash Glucose Monitoring System | Abbott Diabetes Care, Inc. | 2024.04.23 | 通常(Traditional) | |
| 7 | K234133 | Dexcom G7 Continuous Glucose Monitoring System | Dexcom, Inc. | 2024.02.26 | 通常(Traditional) | |
| 8 | K231081 | Dexcom G7 Continuous Glucose Monitoring (CGM) System | Dexcom, Inc. | 2023.05.15 | 特別(Special) | |
| 9 | K223435 | FreeStyle Libre 3 Continuous Glucose Monitoring System; FreeStyle Libre 2 Flash Glucose Monitoring System | Abbott Diabetes Care, Inc. | 2023.04.13 | 通常(Traditional) | |
| 10 | K222447 | FreeStyle Libre 2 Flash Glucose Monitoring System; Freestyle Libre 3 Continuous Glucose Monitoring System | Abbott Diabetes Care, Inc. | 2023.03.03 | 通常(Traditional) | |
| 11 | K223931 | Dexcom G6 Continuous Glucose Monitoring (CGM) System | Dexcom, Inc. | 2023.01.11 | 特別(Special) | |
| 12 | K213919 | Dexcom G7 Continuous Glucose Monitoring System | Dexcom, Inc. | 2022.12.07 | 通常(Traditional) | |
| 13 | K221259 | Dexcom G6 Continuous Glucose Monitoring (CGM) System, Dexcom G6 Glucose Program Continuous Glucose Monitoring (CGM) System, Dexcom G6 Professional Continuous Glucose Monitoring (CGM) System | Dexcom, Inc. | 2022.07.29 | 特別(Special) | |
| 14 | K201328 | Dexcom G6 Continuous Glucose Monitoring (CGM) System | Dexcom, Inc. | 2021.07.15 | 通常(Traditional) | |
| 15 | K200876 | Dexcom G6 Continuous Glucose Monitoring System, Dexcom G6 Glucose Program Continuous Glucose Monitoring System | Dexcom, Inc. | 2020.12.04 | 通常(Traditional) | |
| 16 | K191450 | Dexcom G6 Continuous Glucose Monitoring System, Dexcom G6 Glucose Program Continuous Glucose Monitoring System and Dexcom Pro Q Continuous Glucose Monitoring System | Dexcom, Inc. | 2019.06.28 | 特別(Special) | |
| 17 | K183206 | Dexcom G6 Continuous Glucose Monitoring System | Dexcom, Inc. | 2019.02.14 | 通常(Traditional) | |
| 18 | DEN170088 | Dexcom G6 Continuous Glucose Monitoring System | Dexcom, Inc. | 2018.03.27 | De Novo(Direct) | - |
出典の openFDA は各 510(k) の主要(primary)product code のみを収録しているため、副次コードを含む FDA 公式データベースの検索結果とは件数が異なる場合があります。 FDA 510(k) データベースで確認
PMA(市販前承認)
この product code の PMA 情報はありません。
不具合報告(MAUDE)トレンド
米国不具合報告検索で詳しく見る出典: openFDA(U.S. FDA) のデータをそのまま掲載しています。内容の正確性・最新性は保証されません。FDA が本サイトの内容を承認・保証するものではありません。
報告の存在は、機器と事象の因果関係を意味しません。報告件数を機器間の不具合発生率の比較に用いることはできません。
各データセット(510(k)・PMA・MAUDE・回収・Warning Letter)の解説は 米国FDA情報の概要 を参照してください。
出典: openFDA(U.S. FDA) のデータをそのまま掲載しています。内容の正確性・最新性は保証されません。FDA が本サイトの内容を承認・保証するものではありません。
取得日: 2026.09.28
各データセット(510(k)・PMA・MAUDE・回収・Warning Letter)の解説は 米国FDA情報の概要 を参照してください。